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Abstract
Continuous glucose monitoring (CGM) is well established in the management of diabetes mellitus, but its role in
neonatal glycaemic control is less clear. CGM has provided important insights about neonatal glucose metabolism,
and there is increasing interest in its clinical use, particularly in preterm neonates and in those in whom glucose
control is difficult. Neonatal glucose instability, including hypoglycaemia and hyperglycaemia, has been associated
with poorer neurodevelopment, and CGM offers the possibility of adjusting treatment in real time to account for
individual metabolic requirements while reducing the number of blood tests required, potentially improving long-term
outcomes. However, current devices are optimised for use at relatively high glucose concentrations, and several
technical issues need to be resolved before real-time CGM can be recommended for routine neonatal care. These
include: 1) limited point accuracy, especially at low or rapidly changing glucose concentrations; 2) calibration methods
that are designed for higher glucose concentrations of children and adults, and not for neonates; 3) sensor drift, which
is under-recognised; and 4) the need for dynamic and integrated metrics that can be related to long-term
neurodevelopmental outcomes. CGM remains an important tool for retrospective investigation of neonatal glycaemia
and the effect of different treatments on glucose metabolism. However, at present CGM should be limited to research
studies, and should only be introduced into routine clinical care once benefit is demonstrated in randomised trials.
Keywords: Neonatal hypoglycaemia, Neonatal hyperglycaemia, Interstitial glucose, Continuous glucose monitoring,
Hyperinsulinaemia
Background
Continuous glucose monitoring (CGM) is well estab-
lished in the management of diabetes mellitus, but its
role in neonatal care is less clear. CGM has provided
important insights about neonatal glucose metabolism
[1, 2], and there is increasing interest in its clinical use,
particularly in preterm neonates and in those in whom
glucose control is difficult. Neonatal glucose instability,
including hypoglycaemia and hyperglycaemia, has been
associated with poorer neurodevelopment [3], and
serial blood glucose monitoring by heel lancing is inva-
sive, with potential adverse effects on neurodevelop-
ment [4]. CGM offers the possibility of adjusting
treatment in real time to account for individual
metabolic requirements while reducing the number of
blood glucose measurements required, potentially im-
proving long-term outcomes [5]. However, several
technical issues need to be resolved before CGM can
be recommended for routine neonatal care, including
accuracy, calibration, sensor drift and plasma-
interstitial time delay.
The clinical interpretation of CGM is also challen-
ging. Neonatal studies using CGM have revealed that
variability in glucose concentrations is common both
during neonatal transition [1, 3] and in enterally fed
preterm infants [5–9]. However, the clinical signifi-
cance of these findings is uncertain, and in the absence
of well-established guidelines there is a risk that CGM
could lead to unnecessary or even harmful interven-
tion [3]. Further, while CGM provides more informa-
tion than intermittent blood testing, it is also less
accurate. CGM parameters, therefore, need to be con-
ceptualised as dynamic and integrated rather than as
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static thresholds, and there is little information about
how such parameters should be interpreted.
It is important that clinicians understand the limita-
tions and implications of this rapidly evolving technol-
ogy before it is adopted into clinical practice. This
paper will review: 1) CGM technologies for neonatal
care; 2) insights from CGM about neonatal glucose
metabolism; and 3) the current evidence for the
clinical application of CGM in neonatal intensive care.
CGM technology for neonatal care
Types of CGM
CGM devices measure the glucose concentration of
the interstitial fluid, either in subcutaneous tissue or in
transdermal fluid (Table 1). Subcutaneous biosensors
are of two types: microdialysis fibres and amperomet-
ric needle electrodes. Microdialysis involves insertion
into the subcutaneous tissue of a thin hollow fibre that
is composed of a semipermeable membrane through
which an isotonic fluid containing no glucose is in-
fused [10]. Glucose from the interstitium diffuses into
the fluid stream and is measured by an external en-
zymatic probe. These devices have had only limited
use in neonates in research settings [11, 12], and there
are currently no commercial systems available.
Subcutaneous needle CGM systems consist of a
fine needle sensor connected to a non-implantable
transmitter that powers the sensor and sends raw
data to a monitor, either by cable or Bluetooth. Some
systems display the resulting output in real-time on
the monitor or another linked device; others store
the data for later downloading. The challenge for
sensor manufacturers is to combine all the compo-
nents of an enzymatic ampometric system into a
single needle [13]. Ampometric sensors measure
current flowing from an oxidation (electron produ-
cing) reaction at a working electrode to a reduction
(electron consuming) reaction at a counter electrode.
The working electrode is coated with glucose oxidase
which catalyses the oxidation of glucose when a volt-
age is applied, resulting in transfer of electrons to a
chemical mediator, usually hydrogen peroxide. A ref-
erence electrode is used to ensure a stable voltage is
applied to the working electrode, but reference and
counter electrodes are often combined. In addition,
subcutaneous sensors require a barrier membrane to
limit glucose access to the sensor because of the
deficiency of oxygen in the subcutaneous environ-
ment relative to glucose supply. Each manufacturer
has their own proprietary method for combining
these elements within the needle sensor.
Two main CGM brands have been used in neonates,
Medtronic Minimed (Northridge, CA, United States)
and DexCom (San Diego, CA, United States), both of
which manufacture retrospective and real-time devices.
However, it should be noted that none of these devices
have been approved for clinical use in neonates. The
needle electrodes and transmitters have generally been
placed on the lateral thigh in neonates (Fig. 1), and
have been used for up to 7 days [1, 14]. Some, but not
all babies appear to experience brief pain on insertion
of the needle electrode, but sensors are subsequently
well tolerated in most neonates, and complications are
rare [1, 15].
Raw signal data from the electrode is generated ap-
proximately every 10 s, and is averaged and processed to
give a glucose reading every 5 min, thus providing near-
continuous output. Notably, these devices do not display
Table 1 Methodologies for continuous glucose monitoring
Fluid location Biosensor Advantages Disadvantages Commercial devices currently used in neonates
Subcutaneous Microdialysis fibre with
external amperometric
probe.
Most accurate. Subcutaneous inflammation. Not available
Sensing element is outside












Poor detection with oedema.
Discomfort.
Most require calibration.
Transdermal Glucose binding protein. No skin penetration. Accuracy unknown. Not yet available.
Potentially suitable in
neonates due to their
high trans-epidermal
water loss.
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data when glucose concentrations fall below 2.2 mmol/L
(40 mg/dl), although retrospective analysis and calibra-
tion of the raw signal may still be possible [16]. Subcuta-
neous devices may also fail to give readings in the
presence of significant skin oedema or dehydration, and
with use of vasopressors.
Conversion of the raw signal to a glucose result requires
regular input of calibration measures, i.e., current blood
or plasma glucose concentrations, and thus the resulting
output will reflect the calibration samples used. It is,
therefore, important to understand the effect of sample
type, collection method, analytical delay and assay tech-
nique on calibration values. For example, glucose concen-
tration in whole-blood samples is usually reported to be
lower than in plasma. However, immediate testing of
whole arterial or capillary blood with a ward-based blood
gas analysers can yield very similar glucose concentrations
to laboratory analysis of plasma derived from the same
samples, with a mean processing delay of 30 min [17].
Transdermal sensors are still in development, but in
the future, may be useful in neonates because of their
thin skin layer [18]. They can be divided into those that
rely on passive diffusion of glucose into the transdermal
fluid and those that use reverse iontophoresis to induce
flow of molecules through the skin by applying a small
electrical surface current. Because the concentration
of glucose in the transdermal fluid is very low, signal
transduction relies on specialised glucose binding
proteins that undergo conformational change in the
presence of glucose.
Accuracy and types of error
Like all glucose sensors, CGM accuracy is affected by
random error or noise, which may vary with glucose
concentration [19]. Commonly used point-of-care gluc-
ometers typically have a zero-mean error (deviation from
the true value) of 10% to 30% [20, 21]. However, CGM
error also contains a drift component (Fig. 2) [22]. CGM
measures rely on a continuous shifting internal algo-
rithm to generate a glucose concentration from the raw
sensor signal, based on regular calibration against ‘true’
measurements (blood sample) which are entered into
the device by the clinician or patient. In addition to ran-
dom error, the reported glucose concentration can ‘drift’
from the true measure between calibration measure-
ments and this may significantly impact on accuracy,
particularly if there is a sudden change in glycaemic sta-
tus [16]. Most devices require calibration input at least
every 12 h, with more frequent calibration recom-
mended for increased accuracy.
While random, zero-mean errors can be large in
CGMs due their interstitial location and sensing method,
drift is unseen and thus a major issue in monitoring and
control. For example, drift may result in an apparent
constant CGM glucose reading when blood glucose con-
centration is actually falling. Perhaps worse, drift is gen-
erally not quantified as it is not required for regulatory
approval, even though it has been shown to be problem-
atic in a number of CGM devices [16, 23]. Standard
assessment statistics for sensors, such as mean absolute
relative difference (MARD) [24], indicate overall error
but do not delineate its various components.
A typical CGM device has a MARD of 7% to 12%
[23, 25], which, in adults, can vary based on the
location of the sensor and acuity of the patient [26].
Assessment of drift requires intermediate independent
glucose measurements, but this undermines one of
the key benefits of CGM, namely, reduced blood sam-
pling. Further, it is likely that the level of drift
changes in different clinical situations, and so it is
difficult to be certain about error limits. Nevertheless,
expected ranges have been modelled for several
sensors and devices in adult cohorts [23, 27].
Most CGM devices are designed for type 1 or type 2
diabetes and use a multiple point weighted calibration,
i.e., the algorithm takes into account a weighted average
of the last several ‘true’ calibrating glucose concentra-
tions entered. Multiple point calibration aims to increase
accuracy over the range of calibration points recorded
Fig. 1 Insertion of a continuous glucose sensor and attachment of
transmitter in the lateral thigh of a newborn infant
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because it is assumed that less accurate point-of-care
glucometers will be used for calibration [28]. However,
when the blood glucose concentration deviates from the
previous range of calibration values, calibration may be
less accurate and errors may increase, particularly at low
glucose concentrations [16].
Sensor drift results from altered access to interstitial
fluid or a change in probe surface due to biofilm build
up or corrosion, so that different currents are generated
by the same blood glucose concentration. Multiple point
calibration exacerbates this problem as each measure-
ment can influence calibration for longer. For example,
if a device is calibrated every 8 h using a three-point
calibration method, each measure will influence calibra-
tion for up to 24 h.
In point-to-point calibration, the algorithm interpolates
readings only between one calibration glucose measure
and the next. This avoids the problem of multiple point
calibration exacerbating the error due to sensor drift, and
is suitable for neonatal intensive care where highly accur-
ate glucose measurements are readily available from a
blood gas machine or laboratory analyser (Fig. 3) [16],
However, point-to-point calibration is not employed in
currently available real-time CGM devices for clinical care.
Rather, current devices use proprietary algorithms based
on multiple calibration measures, and the calibration
method can only be changed by the manufacturer. Fortu-
nately, some retrospective devices, such as that produced
by Medtronic MiniMed, output the actual sensor current,
which is very useful in research because it allows the re-
searcher to apply post hoc point-to-point recalibration to
reduce calibration error and ameliorate drift [16].
An additional challenge in achieving accurate CGM
measurements is that calibration must account for the
diffusion of glucose from blood to interstitial fluid. This
imposes not only a variable time delay, but also a low-
pass filter effect, altering the glucose concentration dy-
namics between blood and interstitial fluid [29]. Further,
time delay tends to increase as blood glucose concentra-
tion falls [30, 31], so that there is usually increasing posi-
tive error (CGM reading higher than true blood glucose
concentration) at onset of hypoglycaemia [32]. This
could lead to delayed intervention if CGM were to be
used clinically to monitor for hypoglycaemia. Little is
known of blood-interstitial glucose dynamics in
neonates, although lag times of up to 1 h have been
reported [33].
Fig. 3 Example of neonatal subcutaneous continuous glucose
monitoring (CGM) with retrospective point-to-point calibration
(Data from McKinlay et al. [3])
Fig. 2 Comparison of the types of measurement error for point-of-care (POC) and continuous glucose monitors (CGM), where CGMs can be
prone to drift as well as a zero-centred noise
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Analysis and display of CGM data
Given the measurement errors inherent in real-time
CGM, it cannot be relied upon for point accuracy, par-
ticularly when looking for outlying events, such as
hypoglycaemia. Further, traditional glycaemic metrics
based on exceeding a specified threshold, such as
hypoglycaemic episodes, have limited utility because of
the potentially large zero-mean, random errors. For ex-
ample, in very low birthweight infants, real-time CGM,
had a positive predictive value for hypoglycaemia (blood
glucose <2.6 mmol/L [<47 mg/dl]) of only 40%, and wide
limits of agreement (~ ± 1.5 mmol/L [± 27 mg/dl]) [14].
In another study that measured blood glucose concen-
tration only by point-of-care glucometer, the limits of
agreement for CGM were even wider (~ ± 2.0 mmol/L
[± 36 mg/dl]) [34]. Nevertheless, CGM, with its high
density of data, contains a wealth of information about
glycaemic status that may be of clinical importance.
An alternative approach is to focus on clusters of data
points in moving windows. Although this reduces the
number of independent ‘measures’, it minimises the im-
pact of random errors, while still providing more fre-
quent information than intermittent blood sampling.
Direct filtering is also possible in post hoc analysis [16],
but this is currently not available in real time. Guidelines
for neonatal CGM analysis are yet to be established, but
four main types of metrics should be considered:
i. Time within a desirable band. Studies in adult
intensive care patients suggest that the cumulative
quality of blood glucose control is physiologically
more important than the number of extreme
excursions. For example, patients who spend more
time in the central blood glucose range appear to
have less organ injury and better survival [35–37],
although the extent to which these associations are
causal is a focus of ongoing debate.
ii. Integral (area) under the glycaemic curve. This can
be useful for creating alarm or guardrail systems to
warn of impending clinically significant events. For
example, a diminishing integral has been shown to
be a better marker of impending hypoglycaemia
than a rolling point average [38].
iii. Rising or falling trend. This is the rate of change over
time, which can also be used to warn that a clinical
threshold is about to be exceeded. It should be noted
that the accuracy of trend information is different to
point accuracy, and must be evaluated and monitored
separately. One such tool, the Trend Compass,
appears to be suitable for this purpose [39].
iv. Point-to-point change. In general, changes between
each individual CGM measure should be relatively
small. The distribution of these changes can be used
to determine unlikely or outlying changes in sensor
output [40, 41]. A large number or cluster of such
extreme point-to-point changes can indicate sensor
failure or a marked change in subcutaneous tissue
condition, such as with oedema. Alternatively, they
could be used to detect periodic events that induce
larger glucose changes, such as feeding [41].
Insights from CGM about neonatal glucose
metabolism
Healthy term infants
It is commonly reported that neonatal glucose concentra-
tions decline after birth, reaching a physiological nadir at
approximately 2 h [42]. However, several serial [43] and
cross-sectional [44] studies in healthy, breastfed term
infants have failed to demonstrate any nadir in true
(laboratory) blood glucose concentrations. On the con-
trary, these studies suggest, albeit based on intermittent
sampling, that mean blood glucose concentration remains
stable at approximately 3.0 mmol/L (54 mg/dl) through-
out the first 24 to 48 h, thereafter gradually rising to a
mean of approximately 4.0 mmol/L (72 mg/dl) [45].
CGM offers the possibility of studying early trends in
neonatal glycaemia in greater detail, including effects of
feeding. Several studies have shown that this is feasible
from shortly after birth, although delays between birth
and sensor insertion, and the period of sensor “wetting”
before the output signal stabilises, means that it is diffi-
cult to get reliable measurements in the first 2 h [1, 46].
A study is currently under way in healthy term infants
that is using CGM with retrospective point-to-point re-
calibration based on true blood glucose concentrations,
and will provide important new insights about glucose
dynamics during the neonatal transition (http://hdl.han-
dle.net/2292/32066). This is important because it has
been argued that early transitional hypoglycaemia is a
normal physiological phenomenon, and so does not re-
quire treatment. However, in one population study, even
a single episode of neonatal hypoglycaemia was associ-
ated with poorer performance on later learning, raising
the question of whether all newborns should be screened
for hypoglycaemia rather than just those with risk
factors for impaired metabolic adaptation [47].
At-risk term and near-term infants
A large, prospective cohort study of term and late
preterm infants born at risk of neonatal hypoglycaemia
(the CHYLD Study) included retrospective CGM data
for ≥48 h in 75% of the cohort [3]. Analysis was based
on point-to-point recalibration using all available blood
glucose measures (all by blood gas analyser), thus maxi-
mising accuracy at low glucose concentrations [16]. This
study showed that despite regular blood glucose testing
and a clinical management protocol aimed at maintain-
ing blood glucose ≥2.6 mmol/L [≥47 mg/dl], many
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infants experienced prolonged periods of low interstitial
glucose (<2.6 mmol/L [<47 mg/dl]). For example, 25% of
infants who developed hypoglycaemia spent at least 5 h
with interstitial glucose concentrations <2.6 mmol/L
[<47 mg/dl], and nearly one-quarter of infants with nor-
mal blood glucose concentrations had episodes
(≥10 min) of low interstitial glucose concentrations de-
tected only on CGM, some of which were prolonged [3].
At 2 years of age, 404 infants born at ≥35 weeks’ gesta-
tion underwent detailed neurodevelopmental assessment
[3]. Although hypoglycaemia was not associated with
adverse outcome, CGM showed that those with
neurodevelopmental impairment had higher glucose
concentrations throughout the first 48 h after birth, and
a steeper rise in glucose concentrations after
hypoglycaemia, particularly if episodes were treated with
dextrose rather than feeds alone [3]. These observations
suggest that too rapid a rise or higher, less stable blood
glucose concentrations during recovery from
hypoglycaemia may have adverse effects on the imma-
ture brain. This is supported by animal studies showing
increased generation of reactive oxygen species and
neuronal injury with higher glucose concentrations after
hypoglycaemia [48, 49]. Further, when this cohort was
reassessed at 4.5 years of age, children who had experi-
enced low glucose concentrations detected by CGM but
not by intermittent blood testing had a four-fold in-
creased risk of impaired executive function, whereas the
risk in those identified with, and thus treated for,
hypoglycaemia was increased only two-fold [50]. This
suggests that these clinically undetected changes in glu-
cose concentration may be of physiological significance.
More information is needed from CGM about the effect
of different treatments and feeding strategies on gly-
caemic response, glycaemic stability and later outcomes.
Preterm infants
Since the demonstration that CGM is feasible in very
low birth weight babies [51], it has been shown in pre-
term babies that blood glucose concentrations can fluc-
tuate widely [52] and intermittent blood glucose
sampling commonly fails to detect episodes of both
hyperglycaemia and hypoglycaemia [14, 53, 54]. Indeed,
periods of hypoglycaemia and hyperglycaemia not identi-
fied through intermittent glucose blood testing alone
have been detected by CGM in up to 50% of preterm ba-
bies [2, 5, 55]. Even fully enterally fed preterm babies
may have large fluctuations in their glucose concentra-
tions, varying from hypoglycaemia to hyperglycaemia
within a day, and for several hours at a time [7, 54]. In
one study these fluctuations were related to feed toler-
ance [8], and in another study episodes of hypergly-
caemia were more common in girls and those with fetal
growth restriction [54].
The NIRTURE trial of early insulin treatment was the
first large trial (N = 389) that used CGM without real-
time display to detect hyperglycaemia in very low birth-
weight babies [56]. CGM was well tolerated, even in
babies as young as 23 to 24 weeks’ gestation, with min-
imal interference of nursing cares [51]. Neonatal hyper-
glycaemia was found to be common, with over half of
the babies having a CGM concentration of >10 mmol/L
(>180 mg/dl), and was associated with low gestational
age and birthweight z-score, and inotrope use [53]. It is
important to note that many of the participating centres
in this trial used point-of-care glucometers to calibrate
the CGM devices, and this will have increased CGM
random error [28]. Consequently, there was >10% differ-
ence between CGM and point-of-care measures for ap-
proximately 25% of recordings, and accuracy relative to
true blood glucose (laboratory or blood gas analyser) is
unknown [14].
More recently, a randomised controlled trial in very
low birthweight infants demonstrated that CGM de-
tected nearly three times as many episodes of
hypoglycaemia (<2.8 mmol/L [<50 mg/dl]) during neo-
natal transition than intermittent blood glucose testing,
and the medium duration of each episode was 95 min
[5]. However, this study was also limited by use of point-
of-care glucometers rather than true glucose measure-
ments for both CGM calibration and diagnosis of
hypoglycaemia.
Clinical use of CGM in neonatal intensive care
While use of CGM in neonatal intensive care is attractive
to help improve neonatal glycaemic control and reduced
the numbers of blood tests, there is currently little direct
evidence of the benefits and risks of this technology in ne-
onates. One small randomised trial (N = 43) compared
real-time CGM with intermittent blood glucose monitor-
ing in very low birthweight infants and found that CGM
reduced the median duration of hypoglycemic episodes
<2.8 mmol/L (<50 mg/dl) by 50% (95 vs 44 min) and the
number of capillary blood samples by 25% [5]. However,
infants in the CGM group also received more intravenous
dextrose boluses and total carbohydrate, which could lead
to higher or less stable glucose concentrations and in-
creased total fluid intake, factors that were not reported
but have been associated with increased morbidity [3, 57].
Thus in absence of clinical outcome data, including neu-
rodevelopmental status, the overall balance of risks and
benefits associated with clinical use of CGM in preterm
infants remains uncertain.
There are several clinical situations in which neonatal
glucose management can be particularly difficult and
where optimisation of glycaemic control with CGM may
be more likely to improve outcomes. These include in-
fants with prolonged transitional hypoglycaemia, hypoxic
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ischaemic encephalopathy and preterm infants with
hyperglycaemia. There is a paucity of data about use of
CGM in these subgroups, and further studies are
warranted.
Prolonged transitional hypoglycaemia
In most term and late preterm infants, hypoglycaemia
resolves spontaneously within 1 to 3 days. However, a
smaller group of infants experience persistent
hypoglycaemia, sometimes called “perinatal stress-
induced” or “prolonged transitional” hypoglycaemia, that
can last for several weeks before gradually resolving [58].
These infants have dysregulation of pancreatic beta cells
with associated hyperinsulinism [59], which can be diffi-
cult to manage due to rapidly changing glycaemic status.
These infants likely experience significant subclinical
hypoglycaemia and are at high risk of neurosensory im-
pairment. A real-time CGM system that warned of
impending hypoglycaemia in these infants would poten-
tially allow for a more targeted approach to blood sam-
pling, and may facilitate earlier transition to enteral
feeding and reduce exposure to neuroglycopenia.
Hypoxic ischaemic encephalopathy
Dysglycaemia is common in babies with hypoxic ischemic
encephalopathy [60], and both hypo- and hyperglycaemia
have been associated with reduced survival and poorer
neurological outcome [61]. There is, however, ongoing de-
bate as to whether infants with initial hyperglycaemia have
a more [62] or less [63] favourable response to therapeutic
hypothermia. Current evidence suggests that the aim of
glycaemic management in infants with hypoxic ischaemic
encephalopathy should be careful avoidance of
hypoglycaemia [64, 65] and maintenance of euglycaemia
by regular titration of glucose delivery [65, 66]. This can
be difficult to achieve with intermittent testing, unless
sampling is frequent. Real-time CGM with trend informa-
tion may help achieve greater glucose stability, although
the effect of whole-body cooling on CGM sensor function
is currently not known.
Hyperglycaemia in preterm infants
In very preterm infants, hyperglycaemia is associated
with increased mortality, retinopathy of prematurity,
sepsis and long-term neurodevelopmental impairment
[67, 68], and animal studies indicate that this association
is at least in part causal [69]. Since CGM data has shown
that up to half of very low birth weight infants develop
hyperglycaemia [2, 53], better detection and treatment of
high glucose concentrations may improve outcomes.
However, the benefits of treatment with insulin are un-
certain as insulin infusions substantially increase the risk
of hypoglycaemia, both in very preterm infants [56, 70]
and in children in intensive care [71].
The use of combined CGM, insulin pump and com-
puter algorithm (artificial pancreas) has been shown to
be effective in type 1 diabetics in reducing the fre-
quency and duration of hypoglycaemia [72]. Computer
determined insulin dosing using calculated insulin sen-
sitivity has promise as a management tool in hypergly-
caemic preterm infants [73, 74]. However, there are
currently no data on the use of CGM to inform insulin
management of neonatal hyperglycaemia, although the
use of CGM in conjunction with an insulin infusion
was reported to reduce the number of episodes of
hypoglycaemia in a baby with neonatal diabetes [75].
In paediatric intensive care, use of CGM to guide fre-
quency of blood glucose measurements in a trial of in-
sulin and tight glycaemic control did not prevent
severe hypoglycaemia [71]. However, this study did not
use calculated insulin sensitivity to guide insulin dose
and CGM calibration was based only on point-of-care
glucometers without point-to-point calibration. If
accuracy of real-time CGM can be improved, it may
become possible for very preterm infants with hyper-
glycaemia to be managed with an artificial pancreas to
allow optimal glycaemic control.
Conclusion
CGM offers considerable potential for optimisation of
glycaemia in newborn infants but several issues need
to be addressed before this technology can be recom-
mended for real-time monitoring in neonatal intensive
care. First, devices should ideally be calibrated to
plasma equivalent whole-blood glucose concentrations
measured on a blood gas analyser using a point-to-
point algorithm. Current CGM devices employ multi-
point algorithms that were designed for management
of diabetes mellitus in children and adults using home
glucometers and at higher glucose concentrations.
Real-time calibration methods that are specific to the
neonatal intensive care environment are required.
Second, the potential for sensor drift, which could
result in apparently stable CGM values when blood
glucose concentration is falling, requires further inves-
tigation, including the extent to which it occurs in
neonates and its impact on clinical care. This informa-
tion will be important in determining how frequently
calibration should occur. Third, because CGM has lim-
ited point accuracy, clinical metrics should be based
on integration of multiple GCM values with a focus on
glucose stability, trends and changing metabolic
patterns, rather than exceeding specific thresholds.
Further research is needed to determine which metrics
should be targeted for improving long-term outcomes.
Despite these limitations, retrospective CGM is already
an important tool for understanding neonatal glycaemia
and the effect of different treatments on glucose
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metabolism. Current use of CGM should be limited to
research studies, and this technology should not be in-
troduced into routine clinical care without evidence of
benefit from randomised trials.
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